MARKET

NVCT

NVCT

Nuvectis Pharma, Inc.
NASDAQ
20.81
+0.59
+2.92%
After Hours: 21.20 +0.39 +1.87% 17:23 09/28 EDT
OPEN
20.00
PREV CLOSE
20.22
HIGH
21.24
LOW
19.55
VOLUME
137.91K
TURNOVER
--
52 WEEK HIGH
29.28
52 WEEK LOW
5.55
MARKET CAP
678.02M
P/E (TTM)
-15.9086
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NVCT last week (0921-0925)?
Weekly Report · 14h ago
Nuvectis Oncology Reaffirmed at Buy as Analyst Cites Differentiated BRAF Pipeline and Maintains $30 Price Target
TipRanks · 3d ago
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
TipRanks · 3d ago
Nuvectis Pharma Price Target Maintained With a $39.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
Nuvectis: Buy Rating Reaffirmed as NXP Pipeline Progress and Regulatory Momentum Support Unchanged $39 Price Target
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
Benzinga · 4d ago
Nuvectis Pharma announces NXP200 granted BTD in China
TipRanks · 4d ago
Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
Benzinga · 4d ago
More
About NVCT
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.

Webull offers Nuvectis Pharma Inc stock information, including NASDAQ: NVCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCT stock methods without spending real money on the virtual paper trading platform.